Standard

Activation of nucleus accumbens μ-opioid receptors enhances the response to a glycaemic challenge. / Koekkoek, Laura L.; Kool, Tess; Eggels, Leslie et al.

In: Journal of neuroendocrinology, Vol. 33, No. 10, e13036, 10.2021.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

Koekkoek LL, Kool T, Eggels L, van der Gun LL, Lamuadni K, Slomp M et al. Activation of nucleus accumbens μ-opioid receptors enhances the response to a glycaemic challenge. Journal of neuroendocrinology. 2021 Oct;33(10):e13036. Epub 2021. doi: 10.1111/jne.13036

Author

BibTeX

@article{3a74c0cd0a96466499327b02ea95ff97,
title = "Activation of nucleus accumbens μ-opioid receptors enhances the response to a glycaemic challenge",
abstract = "Opioids are known to affect blood glucose levels but their exact role in the physiological control of glucose metabolism remains unclear. Although there are numerous studies investigating the peripheral effects of opioid stimulation, little is known about how central opioids control blood glucose and which brain areas are involved. One brain area possibly involved is the nucleus accumbens because, as well as being a key site for opioid effects on food intake, it has also been implicated in the control of blood glucose levels. Within the nucleus accumbens, μ-opioid receptors are most abundantly expressed. Therefore, in the present study, we investigated the role of μ-opioid receptors in the nucleus accumbens in the control of glucose metabolism. We show that infusion of the μ-opioid receptor agonist [d-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) in the nucleus accumbens by itself does not affect blood glucose levels, but it enhances the glycaemic response after both an insulin tolerance test, as well as a glucose tolerance test. These findings indicate that the nucleus accumbens plays a role in the central effects of opioids on glucose metabolism, and highlight the possibility of nucleus accumbens μ-opioid receptors as a therapeutic target for enhancing the counter-regulatory response.",
keywords = "DAMGO, glucose metabolism, insulin tolerance test, nucleus accumbens, μ-opioid receptor",
author = "Koekkoek, {Laura L.} and Tess Kool and Leslie Eggels and {van der Gun}, {Luna L.} and Khalid Lamuadni and Margo Slomp and Charlene Diepenbroek and Serlie, {Mireillle J.} and Andries Kalsbeek and {la Fleur}, {Susanne E.}",
note = "Funding Information: This work was supported by an AMC PhD fellowship grant awarded by the AMC Executive Board and by the Netherlands Organization of Scientific Research (NWO‐VICI grant 016.160.617). Funding Information: This work was supported by an AMC PhD fellowship grant awarded by the AMC Executive Board and by the Netherlands Organization of Scientific Research (NWO-VICI grant 016.160.617). Publisher Copyright: {\textcopyright} 2021 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.",
year = "2021",
month = oct,
doi = "10.1111/jne.13036",
language = "English",
volume = "33",
journal = "Journal of neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Activation of nucleus accumbens μ-opioid receptors enhances the response to a glycaemic challenge

AU - Koekkoek, Laura L.

AU - Kool, Tess

AU - Eggels, Leslie

AU - van der Gun, Luna L.

AU - Lamuadni, Khalid

AU - Slomp, Margo

AU - Diepenbroek, Charlene

AU - Serlie, Mireillle J.

AU - Kalsbeek, Andries

AU - la Fleur, Susanne E.

N1 - Funding Information: This work was supported by an AMC PhD fellowship grant awarded by the AMC Executive Board and by the Netherlands Organization of Scientific Research (NWO‐VICI grant 016.160.617). Funding Information: This work was supported by an AMC PhD fellowship grant awarded by the AMC Executive Board and by the Netherlands Organization of Scientific Research (NWO-VICI grant 016.160.617). Publisher Copyright: © 2021 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.

PY - 2021/10

Y1 - 2021/10

N2 - Opioids are known to affect blood glucose levels but their exact role in the physiological control of glucose metabolism remains unclear. Although there are numerous studies investigating the peripheral effects of opioid stimulation, little is known about how central opioids control blood glucose and which brain areas are involved. One brain area possibly involved is the nucleus accumbens because, as well as being a key site for opioid effects on food intake, it has also been implicated in the control of blood glucose levels. Within the nucleus accumbens, μ-opioid receptors are most abundantly expressed. Therefore, in the present study, we investigated the role of μ-opioid receptors in the nucleus accumbens in the control of glucose metabolism. We show that infusion of the μ-opioid receptor agonist [d-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) in the nucleus accumbens by itself does not affect blood glucose levels, but it enhances the glycaemic response after both an insulin tolerance test, as well as a glucose tolerance test. These findings indicate that the nucleus accumbens plays a role in the central effects of opioids on glucose metabolism, and highlight the possibility of nucleus accumbens μ-opioid receptors as a therapeutic target for enhancing the counter-regulatory response.

AB - Opioids are known to affect blood glucose levels but their exact role in the physiological control of glucose metabolism remains unclear. Although there are numerous studies investigating the peripheral effects of opioid stimulation, little is known about how central opioids control blood glucose and which brain areas are involved. One brain area possibly involved is the nucleus accumbens because, as well as being a key site for opioid effects on food intake, it has also been implicated in the control of blood glucose levels. Within the nucleus accumbens, μ-opioid receptors are most abundantly expressed. Therefore, in the present study, we investigated the role of μ-opioid receptors in the nucleus accumbens in the control of glucose metabolism. We show that infusion of the μ-opioid receptor agonist [d-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) in the nucleus accumbens by itself does not affect blood glucose levels, but it enhances the glycaemic response after both an insulin tolerance test, as well as a glucose tolerance test. These findings indicate that the nucleus accumbens plays a role in the central effects of opioids on glucose metabolism, and highlight the possibility of nucleus accumbens μ-opioid receptors as a therapeutic target for enhancing the counter-regulatory response.

KW - DAMGO

KW - glucose metabolism

KW - insulin tolerance test

KW - nucleus accumbens

KW - μ-opioid receptor

UR - http://www.scopus.com/inward/record.url?scp=85114882918&partnerID=8YFLogxK

U2 - 10.1111/jne.13036

DO - 10.1111/jne.13036

M3 - Article

C2 - 34528311

VL - 33

JO - Journal of neuroendocrinology

JF - Journal of neuroendocrinology

SN - 0953-8194

IS - 10

M1 - e13036

ER -

ID: 19720541